Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05967169 · ClinicalTrials.gov registry record · NA

EFS of Bioabsorbable Implant for NSD

A NA study of Nasal Septal Deviation, sponsored by Spirair.

Active
Registry status
NA
Development phase
30
Enrollment target
2
Study locations

NCT05967169: Active NA study of Nasal Septal Deviation, sponsored by Spirair.

NCT05967169 is a NA study of Nasal Septal Deviation that is active but no longer recruiting, run by Spirair. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05967169, a NA study of Nasal Septal Deviation, is active but no longer recruiting, sponsored by Spirair.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

Early feasibility study of bioabsorbable implant and delivery device for correction of septal deviation

Primary Outcome

Feasibility of implantation and durability of Implant through the healing process

Conditions Studied

Interventions

  • DEVICE Nasal Septal Strap implantation

Study Locations (2)

California

  • Breathe Clear Institute - Torrance

Pennsylvania

  • Specialty Physicians - Bethlehem

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-05-25
Est. Completion 2025-12-08
Phase NA
Spirair

3 total trials

What the registry record for NCT05967169 still lists

NCT05967169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Nasal Septal Deviation appearing as the primary indexed condition, and to 1 intervention - of which Nasal Septal Strap implantation is the first listed.

NCT05967169 reports a single indexed study location in California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05967169 about?

NCT05967169 is a clinical study titled "EFS of Bioabsorbable Implant for NSD". Early feasibility study of bioabsorbable implant and delivery device for correction of septal deviation

What is the current status of trial NCT05967169?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-05-25. Estimated completion is 2025-12-08.

What conditions does trial NCT05967169 study?

This clinical trial studies the following conditions: Nasal Septal Deviation.

What interventions are being tested in trial NCT05967169?

The interventions under investigation include: Nasal Septal Strap implantation (DEVICE).

Who is sponsoring clinical trial NCT05967169?

This trial is sponsored by Spirair, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05967169 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nasal Septal Deviation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05967169's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05967169, the US trial registry maintained by the National Library of Medicine. NCT05967169 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.